It may be time to sell Canopy Growth stock.Canopy Growth (CGC -20.76%) stock collapsed in morning trading Friday, down 20.5% through 11 a.m. ET after the company reported a comically bad earnings miss.Heading into today's report, analysts forecast the Canadian cannabis company would lose $0.20 per share in its fourth quarter of fiscal 2025. Instead, Canopy Growth reported a loss of (better sit down for this) $1.32 per share. Canopy Growth's gigantic Q4 missInvestors were not amused.Canopy management tried ...

B&G Foods, Inc. (BGS) posted first-quarter fiscal 2025 results, wherein both top and bottom lines missed the Zacks Consensus Estimate. Both net sales and earnings declined year over year.B&G Foods faced a challenging start to the first quarter of fiscal 2025, impacted by retailer inventory reductions and the timing shift of Easter into the fiscal second quarter. However, the company has seen signs of improving sales trends in recent months. Management remains focused on stabilizing core sales, reshaping the ...

Flutter CEO Peter Jackson told CNBC customer-friendly results in the NCAA's college basketball tournament weighed on overall first-quarter results for FanDuel's parent company. The global sports and online gambling platform reported first-quarter adjusted earnings per share of $1.59, missing Wall Street consensus of $1.89 per share, according to LSEG. Revenue for the period also missed Wall Street expectations, at $3.67 billion versus LSEG estimates of $3.84 billion.The company lowered its full-year U.S. gu ...

财务表现 - 公司第三季度每股收益为1.45美元，低于去年同期的1.71美元，且未达到市场预期 [1] - 第三季度营收同样未达预期，导致股价下跌2.5%至134.96美元 [1] 市场反应 - 股价今日最低跌至129.74美元，但130美元区域似乎起到支撑作用，类似6月和7月的情况 [2] - 年初至今股价累计下跌17% [2] - 多家机构下调目标价，包括摩根士丹利从165美元降至150美元 [1] 期权交易 - 期权交易量达到平日同期的四倍，显示市场活跃度显著上升 [2] - 最受欢迎的合约为5月125美元看跌期权和5月135美元看涨期权 [2] 分析师评级 - 覆盖该股的17家券商中，16家已给出"持有"或更低的评级，但尚未出现评级下调 [1]

核心财务表现 - 2025年第一季度调整后每股收益(EPS)为41美分 低于Zacks共识预期4.6% 同比下滑25.5% [1] - GAAP每股亏损33美分 去年同期亏损4美分 [2] - 总营收3.827亿美元 同比增长3.7% 略超预期0.1% 但有机营收下降3.5% [3] - 公告后股价单日暴跌21.2%至13.28美元 [3] 分业务板块表现 Codman Specialty Surgical部门 - 报告收入2.807亿美元 同比增长9.4% 有机收入下降1.1% [4] - 神经外科产品有机销售额下降4.7% 因多产品线发货停滞 [4] - 器械类有机增长15.1% 受益于强劲需求和有利基数 [4] - ENT业务增长由Acclarent收购驱动 [4] Tissue Technologies部门 - 收入1.02亿美元 同比下滑9.3%(有机下滑9.1%) [5] - DuraSorb/MicroMatrix/Cytal产品实现低双位数增长 [5] - Integra Skin因生产周期问题出现低双位数下滑 [5] - 自有品牌销售下降13.3% 因零部件供应延迟 [5] 利润率与现金流 - 毛利润1.944亿美元 同比下降6% 毛利率收缩526个基点至50.8% [6] - 销售及行政费用增长9.5%至1.815亿美元 研发费用下降8.3%至2470万美元 [6] - 调整后运营亏损1180万美元 去年同期盈利1410万美元 [7] - 季度末现金余额2.391亿美元 较上季度2.464亿美元减少 [8] - 经营活动净现金流出1126万美元 去年同期净流入1576万美元 [8] 业绩指引调整 - 维持2025年营收指引16.5-17.15亿美元(同比增长2.4-6.5%) [9] - 下调全年EPS指引至2.19-2.29美元(原指引2.41-2.51美元) [9] - 预计Q2营收3.9-4亿美元(同比下滑6.8-4.4%) 低于预期的4.178亿美元 [10] - Q2 EPS指引40-45美分 共识预期43美分 [10] 运营亮点与挑战 - 供应链中断(包括发货停滞/生产周期问题/零部件短缺)拖累有机增长 [11] - Acclarent收购贡献积极收入 多产品线实现双位数增长 [12] - 推进合规计划/国际产品组合扩展/管理层补充等战略重点 [12]